¡¡¡¡Õª Òª£º¡¡Ä¿µÄ:̽ÌÖ4ÖÖÑ×Ö¢Òò×ÓIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1ÔÚÑÀÖÜÑ×Óë¹ÚÐIJ¡(CHD)Ïà¹ØÐÔÖеĿÉÄܽÇÉ«,½øÒ»²½Ì½Ë÷ÑÀÖÜÑ׺ÍCHDµÄÏà¹Ø»úÖÆ¡£·½·¨:Ñ¡È¡2015Äê7ÔÂÖÁ2016Äê5Ô¾ÍÕïÓÚÎÂÖÝÊÐÖÐÒ½Ôº¿ÚÇ»¿Æ¼°ÎÂÖÝÊÐÈËÃñÒ½ÔºÐÄÄڿƵÄ129ÀýÑо¿¶ÔÏó,ÆäÖн¡¿µÕß39Ãû,µ¥´¿ÖÐÖضÈÑÀÖÜÑ×»¼Õß35Àý,µ¥´¿CHD»¼Õß31Àý,CHD°éÖÐÖضÈÑÀÖÜÑ×»¼Õß24Àý,²ÉÓö¨ÖƵÄProcartaPlex¶àÒò×ÓELISAÊÔ¼ÁºÐ¼ì²âÿλÊܼìÕßµÄѪÇåIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1º¬Á¿¡£½á¹û:¾Ð·½²î·ÖÎöÅųýΣÏÕÒòËØBMIºÍѪѹµÄ×÷Óúó,¸÷×éѪÇåIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1µÄ²îÒìÓÐͳ¼ÆѧÒâÒå(P<0.05),CHD°éÖÐÖضÈÑÀÖÜÑ××é×î¸ß¡£³ýMCP-1ÒÔÍâ,ÖÐÖضÈÑÀÖÜÑ××éºÍCHD×éѪÇåIL-1β¡¢IL-6¡¢TNF-αˮƽ¾ù¸ßÓÚ½¡¿µ×é¡£½áÂÛ:ÖÐÖضÈÑÀÖÜÑ×»¼ÕßÉý¸ßµÄѪÇåIL-1β¡¢IL-6¡¢TNF-αˮƽ,¿ÉÄÜ´Ù½øCHDµÄ·¢Éú·¢Õ¹¡£
¡¡¡¡¹Ø¼ü´Ê£º¡¡ÑÀÖÜÑ×; ¹ÚÐIJ¡; °×ϸ°û½éËØ1β; °×ϸ°û½éËØ6; Ö×Áö»µËÀÒò×Óα; µ¥ºËϸ°ûÇ÷»¯µ°°×1;
¡¡¡¡Abstract£º¡¡Objective: To study the possible role of inflammatory factors(including IL-1β, IL-6, TNF-α, MCP-1) in the association between periodontal diseases and CHD. Methods: A total of 129 cases were selected from the Department of Stomatology of Wenzhou Chinese Medicine Hospital and the Cardiovascular Department of Wenzhou People's Hospital from July 2015 to May 2016, including 39 healthy swarm(HC group), 35 cases of chronic moderate and severe forms of periodontitis(PD group), 31 cases of coronary heart disease alone(CHD group) and 24 cases of coronary artery disease along with periodontitis(PD+CHD group). The IL-1β, IL-6, TNF-α and MCP-1 in the serum of each recipient were detected by ELISA method. Results: There was statistical difference in IL-1β, IL-6, TNF-α, MCP-1 among enrolled groups(P<0.05).The levels of IL-1β, IL-6, TNF-α and MCP-1 were highest in PD+CHD group, while the levels of IL-1β, IL-6 and TNF-α in PD group and CHD group were higher than those in HC group. Conclusion: The elevated serum levels of IL-1β, IL-6 and TNF-α in patients with moderate to severe periodontitis may promote the progression of CHD.
¡¡¡¡Keyword£º¡¡periodontitis; coronary heart disease; interleukin-1beta; interleukin-6; tumor necrosis factor-alpha; monocyte chemotactic protein 1;
¡¡¡¡ÂýÐÔÑÀÖÜÑ×ÊÇÑÀÖÜ×éÖ¯µÄÂýÐÔ¸ÐȾÐÔ¼²²¡¡£¹ÚÐIJ¡(coronary heart disease,CHD)ÊÇÒ»ÖÖÒÔ¶¯ÂöÖàÑùÓ²»¯(atherosclerosis,AS)Ϊ»ù±¾²¡±äµÄÐÄѪ¹Ü¼²²¡¡£½üÄêÀ´,AS±»ÈÏΪÓëÈ«ÉíÑ×֢ˮƽÉý¸ßÓйØ,ΪÂýÐÔÑ×Ö¢ÐÔ¼²²¡¡£Á÷Ðв¡Ñ§Ñо¿·¢ÏÖÂýÐÔÑÀÖÜÑ×ÓëCHDµÄ·¢Éú·¢Õ¹³ÊÕýÏà¹Ø,ÂýÐÔÑÀÖÜÑ׿ÉÄÜÊÇCHDµÄΣÏÕÒòËØ¡£BECKµÈ[1]¡¢ÑîÁ΢µÈ[2]¾¹ý´óÑù±¾µÄ×·×Ùµ÷²é,·¢ÏÖÑÀÖÜÑ×»¼ÕßµÄCHDΣÏÕ¶ÈÏÔ×ÅÉý¸ß¡£ÁíÓÐÑо¿±íÃ÷ÑÀÖÜÖÎÁÆÓÐÖúÓÚÐÄѪ¹Ü¼²²¡»¼ÕßѪ¹ÜÄÚƤ¹¦ÄܵĸÄÉÆ[3]¡£
¡¡¡¡ÑÀÖܸÐȾ¿Éͨ¹ýÑÀÖÜÖ²¡¾ú¼°Æä´úл²úÎï´Ì¼¤Ñª¹ÜÄÚƤϸ°ûµ¼ÖÂÄÚƤ¹¦ÄÜÕÏ°,´Ó¶ø·¢Éú¶¯ÂöÖàÑùÓ²»¯¡£Ö÷ÒªµÄÑ×Ö¢Òò×Ó,Èç°×½éËØ(interleukin,IL)-1β¡¢IL-6¡¢Ö×Áö»µËÀÒò×Ó-α(tumor necrosis factor,TNF-α)¡¢µ¥ºËϸ°ûÇ÷»¯µ°°×-1(monocyte chemoattractant protein-1,MCP-1)Ò²¿ÉÄܲÎÓëÆäÖÐ,·¢»ÓÐͬ×÷Óᣱ¾Ñо¿Í¨¹ý·ÖÎö½¡¿µÕß¡¢ÖÐÖضÈÑÀÖÜÑ×»¼Õß¡¢µ¥´¿CHD»¼Õß¼°CHD°éÖÐÖضÈÑÀÖÜÑ×»¼ÕßµÄѪÇåIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1ËÄÖÖÑ×Ö¢Òò×Óˮƽ,̽ÌÖÒÔÉÏÑ×Ö¢Òò×ÓÔÚÑÀÖÜÑ׺ÍCHDÏà¹ØÐÔÖеÄ×÷Óá£
¡¡¡¡1¡¢ ¶ÔÏóºÍ·½·¨
¡¡¡¡1.1¡¢ ¶ÔÏó
¡¡¡¡Ñ¡È¡2015Äê7ÔÂÖÁ2016Äê5Ô¾ÍÕïÓÚÎÂÖÝÊÐÖÐÒ½Ôº¿ÚÇ»¿Æ¼°ÎÂÖÝÊÐÈËÃñÒ½ÔºÐÄÄڿƵÄ129ÀýÑо¿¶ÔÏó¡£ÆäÖн¡¿µÕß39Àý(HC×é),ÖÐÖضÈÑÀÖÜÑ×»¼Õß35Àý(PD×é),µ¥´¿CHD»¼Õß31Àý(CHD×é),CHD°éÖÐÖضÈÑÀÖÜÑ×»¼Õß24Àý(PD+CHD×é)¡£ÄÉÈë±ê×¼:(1)ÄêÁä40¡«65Ëê;(2)ÊÔÑéÇ°1¸öÔÂÄÚδ·þÓÿ¹¾úÒ©Îï;(3)ÊÔÑéÇ°6¸öÔÂÄÚÎÞÑÀÖÜÖÎÁÆÊ·;(4)¸¾Å®Î´ÈÑÉï;(5)ÎÞÒû¾Æ¡¢ÎüÑ̵ÈÊȺá£ÆäÖÐCHDµÄÕï¶Ï±ê×¼:×ó¹Ú×´¶¯ÂöÇ°½µÖ§¡¢»ØÐýÖ§»òÓÒ¹ÚÂö¼°Æä·ÖÖ§ÖС¢»ò×óÖ÷¸É´æÔÚ>50%Ö±¾¶µÄ¹Ì¶¨ÐÔÏÁÕ»ò×èÈûÐÔ²¡±ä¡£¸ù¾ÝARMITAGEµÈ[4]±¨µÀ,ÑÀÖܽ¡¿µ»òö¸Ñ×µÄÕï¶Ï±ê×¼:È«¿ÚÑÀƽ¾ùÁÙ´²¸½×Åɥʧ(clinical attachment loss,CAL)≤0.5 mm,ͬʱÁÚÃæCAL≥3 mmµÄλµã=0,ÇÒʧÑÀÊý≤2¡£ÖÐÖضÈÂýÐÔÑÀÖÜÑ×µÄÕï¶Ï±ê×¼ÈçÏÂ:È«¿ÚÑÀƽ¾ùCAL≥1.6 mm,ͬʱÁÚÃæCAL≥3 mmµÄλµã·Ö²¼ÓÚ3¸ö²»Í¬Çø¶Î»òÖÁÉÙÓÐ6¿ÅÑÀ,ÇÒʧÑÀÊý≤14¡£±¾Ñо¿»ñÕã½ÖÐÒ½Ò©´óѧ¸½ÊôÎÂÖÝÊÐÖÐÒ½ÔºÂ×ÀíίԱ»áÅú×¼,ËùÓÐÑо¿¶ÔÏó¾ùÖªÇéͬÒâ¡£
¡¡¡¡1.2¡¢ Ö÷ÒªÊÔ¼ÁÓëÒÇÆ÷
¡¡¡¡IL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1¶àÒò×ÓELISA¼ì²âÊÔ¼ÁºÐ(º¼ÖÝÁª¿ÆÉúÎï¼¼ÊõÓÐÏÞ¹«Ë¾)¡¢ÒºÏàоƬ·ÖÎöϵͳ(ÃÀ¹úLuminex¹«Ë¾)¡¢Ã¸±êÒÇ(ÃÀ¹úThermo¹«Ë¾)¡¢Õñµ´Æ÷(½ËÕÆäÁÖ±´¶ûÒÇÆ÷ÖÆÔìÓÐÏÞ¹«Ë¾)¡¢ÎÐÐý»ìºÏÆ÷(½ËÕÆäÁÖ±´¶ûÒÇÆ÷ÖÆÔìÓÐÏÞ¹«Ë¾)¡¢ÀëÐÄ»ú(½ËÕÆäÁÖ±´¶ûÒÇÆ÷ÖÆÔìÓÐÏÞ¹«Ë¾)¡£
¡¡¡¡1.3¡¢ ·½·¨
¡¡¡¡1.3.1¡¢ ÁÙ´²¼ì²é:
¡¡¡¡¼Ç¼ÿλÑо¿¶ÔÏóÈ«¿ÚÑÀ(³ýµÚÈýÄ¥ÑÀÍâ)µÄÑÀÖÜ×´¿ö¼ì²â½á¹û¡£¼ì²éÄÚÈÝ°üÀ¨Ì½Õï³öѪ(bleeding on probing,BOP)¡¢ÑÀÖÜ´ü̽ÕïÉî¶È(pocket probing depth,PPD)¡¢CAL¡£²âÁ¿Ã¿¿ÅÑÀµÄ¼Õ¡¢Éà²àÔ¶ÖС¢ÕýÖкͽüÖÐ6¸öλµã,ȡƽ¾ùÖµ×÷Ϊ¸ÃÑÀ²âÁ¿½á¹û,È«¿ÚÑÀƽ¾ùÖµ×÷Ϊ¸ÃÑо¿¶ÔÏóµÄ²âÁ¿½á¹û¡£¼Ç¼ËùÓÐÑо¿¶ÔÏóµÄѪѹ¡¢BMIµÈÐÅÏ¢¡£
¡¡¡¡1.3.2¡¢ ѪÇåÑù±¾µÄÊÕ¼¯¼°ÖƱ¸:
¡¡¡¡ËùÓÐÄÉÈëµÄÊܼìÕß³éÈ¡¿Õ¸¹¾²ÂöѪ5 mL,¾²ÖÃ1 hºó,ÓÃ4¡æµÍÎÂÀëÐÄ»ú(3 000 r/min)ÀëÐÄ10 min,µÃµ½ÑªÇåÑù±¾,µÇ¼Ç±àºÅ,-70¡æ¶³´æ¡£
¡¡¡¡1.3.3¡¢ ѪÇåÏà¹ØÑ×Ö¢Òò×ÓˮƽµÄ²â¶¨:
¡¡¡¡ÑªÇå±ê±¾ÔÚÊÒÎÂÏÂÈÚ½â,²ÉÓÃProcarta Plex¶àÒò×ÓELISAÊÔ¼ÁºÐ¼ì²âѪÇåÖÐIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1µÄº¬Á¿¡£ÓÃProcarta Plex Analyst 1.0 SoftwareÈí¼þ¼ÆËã,ÒÔ±ê׼ƷŨ¶ÈΪºá×ø±ê,MFIֵΪ×Ý×ø±ê,½øÐÐÎå²ÎÊýLogarithmic axis»Ø¹éÄâºÏÉú³É±ê×¼ÇúÏß¡£
¡¡¡¡1.4¡¢ ͳ¼Æѧ´¦Àí·½·¨
¡¡¡¡²ÉÓÃSPSS13.0Èí¼þ°ü½øÐÐͳ¼Æѧ·ÖÎö¡£¸÷×é¼äIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1ˮƽµÄ±È½Ï²ÉÓõ¥ÒòËØ·½²î·ÖÎö,¶àÖرȽϲÉÓÃSNK·¨,¼ÆÊý×ÊÁϲÉÓÃχ2¼ìÑé,УÕý»ìÔÓÒòËزÉÓÃз½²î·ÖÎö¡£P<0.05Ϊ²îÒìÓÐͳ¼ÆѧÒâÒå¡£
¡¡¡¡2¡¢ ½á¹û
¡¡¡¡2.1¡¢ Ò»°ãÇé¿ö
¡¡¡¡¸÷×é¼äÐÔ±ð¡¢ÄêÁä¡¢½ÌÓý³Ì¶È¡¢Ö°ÒµÇé¿ö²îÒìÎÞͳ¼ÆѧÒâÒå(P>0.05),ÔÚ¸÷×é»ù±¾Æ½¾ù·Ö²¼¡£¼û±í1¡£ÆäÖÐCHD×é¡¢PD+CHD×黼ÕßµÄѪѹ¡¢BMIÏÔןßÓÚHC×éºÍPD×é(P<0.05),¶øHC×éºÍPD×éÖ®¼äÒÔ¼°CHD×éºÍPD+CHD×éÖ®¼äµÄѪѹ¡¢BMI²îÒìÔòÎÞͳ¼ÆѧÒâÒå(P>0.05)¡£¼û±í2¡£
¡¡¡¡2.2 ¡¢ÑÀÖÜÁÙ´²Ö¸Êý
¡¡¡¡CAL³ýHC×éÓëCHD×é¼ä²îÒìÎÞͳ¼ÆѧÒâÒåÍâ,ÔÚÆäÓà×é¼ä²îÒì¾ùÓÐͳ¼ÆѧÒâÒå(P<0.05);PD×éµÄCALÖµ×î¸ß,HC×éºÍCHD×é×îµÍ¡£ËùÓÐ×é¼äPPD²îÒì¾ùÓÐͳ¼ÆѧÒâÒå(P<0.05);PD+CHD×é¡¢PD×é¡¢CHD×é¡¢HC×éÒÀ´ÎϽµ¡£³ýHC×éÓëCHD×é¼ä¡¢PD×éÓëPD+CHD×é¼äBOP²îÒìÎÞͳ¼ÆѧÒâÒåÍâ,ÆäÓà×é¼äBOP²îÒì¾ùÓÐͳ¼ÆѧÒâÒå(P<0.05);PD×é¡¢PD+CHD×é¸ßÓÚHC×éºÍCHD×é¡£¼û±í2¡£
¡¡¡¡2.3¡¢²»Í¬ÑÀÖÜ״̬ÕßCHD·¢²¡±È½Ï
¡¡¡¡±¾¿ÎÌâ×éÕë¶ÔͬһÑо¿¶ÔÏóµÄÇ°ÆÚϵÁÐÑо¿¹¤×÷ÒÑ֤ʵ:¾¶àÔªlogistic»Ø¹é·ÖÎö,ÔÚÅųýÁËѪѹ¡¢BMIµÄ»ìÔÓ×÷Óúó,ÖÐÖضÈÂýÐÔÑÀÖÜÑ×Ôö¼Ó»¼CHDµÄ·çÏÕ(OR=2.555,95%CI=1.096¡«5.958)[5]¡£
¡¡¡¡2.4 ¡¢4×é¼ä4ÖÖÑ×Ö¢Òò×ӵıȽÏ
¡¡¡¡ÔÚ²»ÅųýBMI¡¢ÑªÑ¹µÈÓ°ÏìµÄÇé¿öÏÂ,¸÷×éѪÇåIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1Ö®¼äµÄ²îÒìÓÐͳ¼ÆѧÒâÒå(P<0.01)¡£×é¼äÁ½Á½±È½Ï½á¹û±íÃ÷:IL-1βˮƽÔÚ¸÷×é¼ä²îÒì¾ùÓÐͳ¼ÆѧÒâÒå,PD+CHD×é×î¸ß,CHD×éÆä´Î,PD×é´ÎÖ®,¾ù½ÏHC×é¸ß(P<0.05);¾ÍIL-6¶øÑÔ,³ýÁËPD×éÓëCHD×éµÄ²îÒìÎÞͳ¼ÆѧÒâÒå(P>0.05)ÒÔÍâ,ÆäÓà×é¼ä²îÒì¾ùÓÐͳ¼ÆѧÒâÒå(P<0.05),PD+CHD×é×î¸ß,HC×é×îµÍ;TNF-αÓëIL-6ÀàËÆ,³ýÁËPD×éÓëCHD×é¼äµÄ²îÒìÎÞͳ¼ÆѧÒâÒå(P>0.05)ÒÔÍâ,ÆäÓà¸÷×é¼äTNF-α²îÒì¾ùÓÐͳ¼ÆѧÒâÒå(P<0.05),PD+CHD×é×î¸ß,HC×é×îµÍ;MCP-1µÄ±í´ïÔÚHC×éÓëPD×éÖ®¼ä²îÒìÎÞͳ¼ÆѧÒâÒå(P>0.05),ÔÚPD×éÓëCHD×éÖ®¼ä²îÒìÒàÎÞͳ¼ÆѧÒâÒå(P>0.05),ÆäÓà×é¼ä²îÒì¾ùÓÐͳ¼ÆѧÒâÒå(P<0.05),PD+CHD×é×î¸ß,¼ûͼ1¡£
¡¡¡¡±í1 4×éÑо¿¶ÔÏóÒ»°ãÇé¿ö
¡¡¡¡×¢:¸÷×é¼ä²îÒì¾ùÎÞͳ¼ÆѧÒâÒå(P>0.05)
¡¡¡¡±í2 4×éÑо¿¶ÔÏóѪѹ¡¢BMI¡¢ÑÀÖÜÁÙ´²Ö¸ÊýµÄ±È½Ï
¡¡¡¡ÓëHC×é±È£ºaP<0.05£»ÓëPD×é±È£ºbP<0.05£»ÓëCHD×é±È£ºcP<0.05
¡¡¡¡¾Ð·½²î·ÖÎöУÕý»ìÔÓÒòËØBMIºÍѪѹµÄÓ°Ïìºó,½á¹ûÏÔʾ,¸÷×éѪÇåIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1ˮƽµÄ²îÒìÈÔ¾ßÓÐͳ¼ÆѧÒâÒå(P<0.01)¡£¾SNK·¨¶àÖرȽϱíÃ÷,¸÷×é¼ä4ÖÖÑ×Ö¢Òò×ÓˮƽµÄ²îÒìÓëδУÕýÇ°Ò»Ö¡£
¡¡¡¡3¡¢ ÌÖÂÛ
¡¡¡¡ÂýÐÔÑÀÖÜÑ׺ÍCHD½ÔÊÇÂýÐÔ¸ÐȾÐÔ¼²²¡¡£±¾¿ÎÌâ×éÇ°ÆÚϵÁÐÑо¿·¢ÏÖ,ÖÐÖضÈÂýÐÔÑÀÖÜÑ×ÓëCHDµÄ·¢²¡ÏÔ×ÅÏà¹Ø(OR=2.555,95%CI=1.096¡«5.958)¡£ÑÀÖÜÑ×ÊÇÈçºÎ´Ù½øCHDµÄ·¢Éú·¢Õ¹ÒÔ¼°ËüÃǵÄÏà¹Ø»úÖÆ,һֱΪÈËÃÇËù¹Ø×¢¡£
¡¡¡¡CHD×÷Ϊ¶àÒòËؼ²²¡,Ò׸лùÒò¡¢»·¾³ÒòËصȶ¼Ó°ÏìÆä·¢Éú·¢Õ¹¡£ASÐγɵĹý³ÌʼÓÚ¶ÔѪ¹ÜÄÚƤϸ°ûµÄËðÉË¡£µ±Êܵ½»úе¡¢Éú»¯»òÃâÒßÔÒòµÈ´Ì¼¤Ê±,Ѫ¹ÜÄÚƤϸ°û¹¦ÄÜÕÏ°,Ѫ¹ÜÄÚƤͨ͸ÐÔÔö¼Ó,Òý·¢Ñ×Ö¢³õʼ½×¶Î¡£½ø¶øѪ¹ÜÄÚƤϸ°û±í´ïµÄ𤸽·Ö×Ó´Ù½øµ¥ºËϸ°û𤸽ÓÚÄÚƤ,ÍÌÊÉÑ»·ÑªÒºÖеÄÑõ»¯µÍÃܶÈÖ¬Öʵ°°×,½øÒ»²½ÊÍ·ÅÑ×Ö¢Òò×Ó[6]¡£Òò¶ø,Ñ×Ö¢ÊÇÒýÆðÉÏÊö²¡Àí¹ý³ÌµÄÖØҪʼ¶¯ºÍÐͬÒòËØÖ®Ò»¡£´ËÍâ,ÓÐÑо¿ÒѾ֤ʵÁ˶àÖÖ²¡ÔÌåÔÚAS²¡±äÖз¢»Ó×÷ÓÃ,°üÀ¨·ÎÑ×ÒÂÔÌå¡¢ÓÄÃÅÂÝÐý¸Ë¾ú¡¢¾Þϸ°û²¡¶¾ºÍÑÀÖÜÖ²¡¾úµÈ[7]¡£¶¯ÎïÄ£ÐÍÑо¿Öз¢ÏÖÕâЩ²¡ÔÌå¿ÉÒÔÆô¶¯ºÍ¼ÓËÙAS¡£¿¹ÉúËصÄʹÓÿÉÒÔ½µµÍ·¢ÉúµÚÒ»´Î¼±ÐÔÐļ¡¹£ÈûµÄ·çÏÕ[8]¡£ÔÚÇ°Õ°ÐÔµÄÑо¿Öз¢ÏÖ,³£¼ûµÄÂýÐÔ¸ÐȾ°üÀ¨ºôÎüµÀ¡¢Äò·ºÍÑÀÖܸÐȾµÈ¶¼ÄÜÏÔ×ÅÔö¼Ó·¢Éú¾±¶¯ÂöASµÄ·çÏÕ,¼´Ê¹ÊܼìÕßÔÚûÓд«Í³Î£ÏÕÒòËصÄÇé¿öÏÂÒàÈç´Ë[9]¡£
¡¡¡¡ÑÀÖÜÑ××÷Ϊ¸ÐȾÐÔ¼²²¡,Æäʼ¶¯Òò×ÓÊÇÑÀ¾ú°ß,ö¸Ï¾ú°ßϸ¾ú¼°Æ䶾ÐÔ²úÎï¿Éͨ¹ýѪѻ·À©É¢ÒýÆð¾úѪ֢,´Ó¶ø¿É»î»¯Ñª¹ÜÄÚƤϸ°û,µ¼ÖÂѪ¹Ü¾Ö²¿µÄÑ×Ö¢·´Ó¦,´Ù½øASµÄ·¢Éú·¢Õ¹¡£KOZAROVµÈ[10]¡¢NAKANOµÈ[11]¡¢YAMAZAKIµÈ[12]¶¼´Ó»¼ÕßµÄAS°ß¿éÖмì²âµ½ÊýÖÖÑÀÖÜÖ²¡¾úµÄ´æÔÚ¡£Óж¯ÎïÑо¿[13,14]·¢ÏÖÑÀÖÜÖ²¡¾ú¿Éͨ¹ý½éµ¼Ö¬ÖʵÄÑõ»¯ºÍ³Á»ýÀ´´Ù½øAS°ß¿éµÄÐγɡ£
¡¡¡¡ÑÀÖÜϸ¾ú²úÉúµÄ¶¾ËØ¡¢¿¹Ô³É·Ö¡¢´úл²úÎïµÈ,»¹¿É´Ì¼¤ÉÏƤϸ°û²úÉú´óÁ¿Ñ×Ö¢Òò×Ó,ÈçIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1µÈ¡£ÒÑÓÐÑо¿±íÃ÷ÑÀÖÜÑ×»¼ÕßѪÇå»òö¸¹µÒºÖÐIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1ˮƽ±ÈÑÀÖܽ¡¿µÕ߸ß[15,16,17,18],ÕâÓë±¾Ñо¿½á¹ûÏàËÆ¡£ÕâЩÑ×Ö¢Òò×ÓÖ®¼ä´æÔÚÐͬ×÷ÓÃ,ÈçIL-1β¿É´Ù½øIL-6¡¢IL-8¡¢TNF-α¡¢MCP-1¡¢CRPµÈ±í´ï,¼ÓËÙASÐγÉ[19]¡£ÑªÇåÖÐÑ×Ö¢Òò×ÓµÄÔö¼Ó¿ÉÄÜͨ¹ýÒÔÏÂ;¾¶Ó°ÏìASµÄ·¢Éú·¢Õ¹:(1)ͨ¹ý¶ÔѪ¹ÜÄÚƤϸ°ûµÄÖ±½ÓËðÉË,ʹѪ¹Üͨ͸ÐÔÔö¼Ó,ÒÔÖµ¨¹Ì´¼Ò×´©Í¸Ñª¹ÜÄÚĤ,ÔÚÄÚĤϳÁµíÐγÉÖàÑù°ß¿é¡£(2)´Ù½øµ¥ºË¾ÞÊÉϸ°ûÉãÈëLDL,´Ó¶ø´Ù½øÐγÉÖ¬ÖÊÌõÎÆ¡£(3)´Ù½øƽ»¬¼¡Ï¸°û¡¢°×ϸ°ûÏòѪ¹ÜÄÚƤϽþÈó¡¢¾Û¼¯,¶øʹÄÚĤÔöºñ,´Ù½øASÐγɡ£(4)ͨ¹ý¸÷ÖÖ;¾¶ÒÖÖÆÏËÈÜ,´Ù½øѪ˨Ðγɡ£ÁíÓÐÑо¿[20,21,22]±íÃ÷,ÑÀÖÜ»ù´¡ÖÎÁÆ¿ÉʹѪÇåÖÐÑ×Ö¢Òò×ÓIL-1β¡¢IL-6¡¢TNF-α¡¢CRPµÈµÄˮƽ½µµÍ,¶øÇÒѪÇåTC¡¢TG¡¢DL-CˮƽҲÓнµµÍ,ÌáʾÑÀÖÜÖÎÁÆ¿ÉÓ°ÏìCHDµÄ·¢Éú·¢Õ¹¡£
¡¡¡¡Í¼1 4×éÑо¿¶ÔÏóѪÇåIL-1β¡¢IL-6¡¢TNF-α¡¢MCP-1ˮƽµÄ±È½Ï
¡¡¡¡ÓëHC×é±È£ºaP<0.05£»ÓëPD×é±È£ºbP<0.05£»ÓëCHD×é±È£ºcP<0.05
¡¡¡¡´ËÍâ,ÑÀÖÜÖ²¡¾ú´Ù½øASµÄÐγɺͽøÕ¹»¹¿ÉÄÜÓëÒÔÏ»úÖÆÓйØ:(1)ÑÀÖÜÑ×ʱ¿¹ÑÀö¸ß²ßøµ¥°û¾ú(P.g)µÄÃâÒß·´Ó¦ÓëѪ¹ÜÄÚƤϸ°û±í´ïµÄHSP-60Ðγɽ»²æ·´Ó¦¡£Ñо¿±íÃ÷,Ëæ×ÅÑÀÖÜÖ²¡¾ú×ܸºµ£(Ö÷ÒªÊÇP.g¡¢°é·ÅÏß·ÅÏ߸˾ú¡¢ËóÐθ˾ú)µÄÔö¼Ó,ÈËѪÇåÖÐHSP-60µÄ¿¹ÌåˮƽҲËæÖ®Éϵ÷[23]¡£(2)P.gµÄÂýÐÔ¸ÐȾ»¹¿Éͨ¹ýÔö¼Ó𤸽·Ö×ÓÈçϸ°û¼ä𤸽·Ö×Ó-1¡¢Ñª¹Üϸ°û𤸽·Ö×Ó-1µÈ´Ù½øµ¥ºËϸ°û¾Û¼¯ÔÚѪ¹ÜÄÚƤ,´Ó¶øµ¼ÖÂAS¡£(3)ѪÁ´Çò¾ú¡¢P.gµÈ»¹¿É´Ù½øѪС°åÔÚѪ¹ÜÄÚÄý¼¯,ÐγÉѪ˨²¢Ë¨ÈûѪ¹Ü,µ¼ÖÂÐļ¡¹£ËÀ¡¢ÄÔ¹£ËÀµÈ¼±Ö¢¡£
¡¡¡¡±¾Ñо¿½á¹û·¢ÏÖ,ÖÐÖضÈÑÀÖÜÑ×µÄIL-1β¡¢IL-6¡¢TNF-αˮƽÏÔןßÓÚ½¡¿µÕß(P<0.05)¡£ÖÐÖضÈÑÀÖÜÑ×ÓëCHD¹²»¼ÕßµÄIL-1β¡¢IL-6¡¢TNF-αˮƽÒàÏÔןßÓÚ½öÓÐÑÀÖÜÑ×Õß»òCHD»¼Õß(P<0.05)¡£ÕâÌáʾ,ÑÀÖܸÐȾ¿ÉÌá¸ßϵͳÑ×Ö¢Òò×ÓµÄˮƽ,¶øÕâЩÑ×Ö¢Òò×ÓˮƽµÄ±ä»¯ÓÖ´Ù½øCHDµÄ·¢Éú·¢Õ¹¡£
¡¡¡¡×ÛÉÏËùÊö,ÖÐÖضÈÑÀÖÜÑ׿ÉÄÜͨ¹ýÉϵ÷ѪÇåIL-1β¡¢IL-6¡¢TNF-αµÄˮƽ,ÓëCHDµÄ·¢Éú·¢Õ¹Óйء£Í¬Ê±,ÕâЩÑ×Ö¢Òò×ÓÒ»¶¨³Ì¶ÈÉÏ¿ÉÒÔÔ¤²âAS¡¢Ðļ¡¹£ËÀ¡¢ÄÔ×äÖкÍѪ˨ÐγɵĸÅÂÊ¡£
¡¡¡¡²Î¿¼ÎÄÏ×
¡¡¡¡[1] BECK J D, EKE P, HEISS G, et al. Periodontal disease and coronary heart disease:a reappraisal of the exposure[J].Circulation, 2005, 112(1):19-24.
¡¡¡¡[2]ÑîÁ»Õ,Á¬Ã··Æ,ºúÖÓÔÂ,µÈ.ÂýÐÔÑÀÖÜÑ×Óë¸ß֬Ѫ֢Ïà¹ØÐÔµÄMeta·ÖÎö[J].»ªÎ÷¿ÚǻҽѧÔÓÖ¾, 2017, 35(4):419-426.
¡¡¡¡[3] BLUM A, KRYUGER K, MASHIACH EIZENBERG M,et al. Periodontal care may improve endothelial function[J].Eur J Intern Med, 2007, 18(4):295-298.
¡¡¡¡[4] ARMITAGE G C, WU Y, WANG H Y, et al. Low prevalence of a periodontitis-associated interleukin-1composite genotype in individuals of Chinese heritage[J]. J Periodontol, 2000, 71(2):164-171.
¡¡¡¡[5] Íõ²ÊÇí.Ïà¹Ø𤸽·Ö×ÓÔÚÑÀÖÜÑ×Óë¹ÚÐIJ¡Ïà¹ØÐÔÖеÄ×÷Óóõ̽[D].ÎÂÖÝ:ÎÂÖÝÒ½¿Æ´óѧ, 2016.
¡¡¡¡[6] BLANKENBERG S, BARBAUX S, TIRET L. Adhesion molecules and atherosclerosis[J]. Atherosclerosis, 2003,170(2):191-203.
¡¡¡¡[7] CULLINAN M P, SEYMOUR G J. Periodontal disease and systemic illness:will the evidence ever be enough[J].Periodontology, 2000, 62(1):271-286.
¡¡¡¡[8] ?STERGAARD L, S?RENSEN H T, LINDHOLT J, et al.Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins:a comparative prospective cohort study[J]. J Infect Dis, 2001, 183(11):1625-1630.
¡¡¡¡[9] KIECHL S, EGGER G, MAYR M, et al. Chronic infections and the risk of carotid atherosclerosis:prospective results from a large population study[J]. Circulation, 2001, 103(8):1064-1070.
¡¡¡¡[10] KOZAROV E, SWEIER D, SHELBURNE C, et al.Detection of bacterial DNA in atheromatous plaques by quantitative PCR[J]. Microbes Infect, 2006, 8(3):687-693.
¡¡¡¡[11] NAKANO K, INABA H, NOMURA R, et al. Distribution of Porphyromonas gingivalis fimA genotypes in cardiovascular specimens from Japanese patients[J]. Oral Microbiol Immunol, 2008, 23(2):170-172.
¡¡¡¡[12] YAMAZAKI K, HONDA T, DOMON H, et al. Relationship of periodontal infection to serum antibody levels to periodontopathic bacteria and inflammatory markers in periodontitis patients with coronary heart disease[J]. Clin Exp Immunol, 2007, 149(3):445-452.
¡¡¡¡[13] MAEKAWA T, TAKAHASHI N, TABETA K, et al. Chronic oral infection with Porphyromonas gingivalis accelerates atheroma formation by shifting the lipid profile[J]. PLoS One, 2011, 6(5):e20240.
¡¡¡¡[14] ANDRIANKAJA O, TREVISAN M, FALKNER K, et al.Association between periodontal pathogens and risk of nonfatal myocardial infarction[J]. Community Dent Oral Epidemiol, 2011, 39(2):177-185.
¡¡¡¡[15] BUDUNELI N, KINANE D F. Host-derived diagnostic markers related to soft tissue destruction and bone degradation in periodontitis[J]. J Clin Periodontol, 2011, 38Suppl 11:85-105.
¡¡¡¡[16]ÁÖ÷,ÕŶ¬Ñ©,Áõ־ǿ,µÈ.ÂýÐÔÑÀÖÜÑ×»¼ÕßѪÇåIL-33¡¢TNF-α¡¢IL-6µÄ¼ì²â¼°ÒâÒå[J].Ê׶¼Ò½¿Æ´óѧѧ±¨, 2016,37(3):255-259.
¡¡¡¡[17]ÎâæÃ,ËïÇÕ·å,Ñîاɽ,µÈ.ÂýÐÔÑÀÖÜÑ×Óë¹ÚÐIJ¡»¼ÕßѪÇåÑ×Ö¢Òò×Óº¬Á¿¼°Æä×÷ÓõÄÏà¹ØÑо¿[J].Öлª¿ÚǻҽѧÔÓÖ¾, 2010, 45(5):265-268.
¡¡¡¡[18] GUNPINAR S, ALPTEKIN N O, DUNDAR N. Gingival crevicular fluid levels of monocyte chemoattractant protein-1in patients with aggressive periodontitis[J]. Oral Dis, 2017,23(6):763-769.
¡¡¡¡[19] DINARELLO C A. A clinical perspective of IL-1βas the gatekeeper of inflammation[J]. Eur J Immunol, 2011, 41(5):1203-1217.
¡¡¡¡[20] ZHOU S Y, DUAN X Q, HU R, et al. Effect of non-surgical periodontal therapy on serum levels of TNF-a, IL-6 and C-reactive protein in periodontitis subjects with stable coronary heart disease[J]. Chin J Dent Res, 2013, 16(2):145-151.
¡¡¡¡[21]²ÜÖ±,ÍõÑÇÁá,ÁõÖ¾ÔÆ.ÑÀÖܸÉÔ¤ÖÎÁƶÔÑÀÖÜÑ×°é¹ÚÐIJ¡»¼ÕßѪ֬ˮƽ¼°Ñ×Ö¢Òò×ÓµÄÓ°Ïì[J].¿Úǻҽѧ, 2016,36(8):710-713.
¡¡¡¡[22] D’AIUTO F, READY D, TONETTI M S. Periodontal disease and C-reactive protein-associated cardiovascular risk[J]. J Periodontal Res, 2004, 39(4):236-241.
¡¡¡¡[23] LEISHMAN S J, FORD P J, DO H L, et al. Periodontal pathogen load and increased antibody response to heat shock protein 60 in patients with cardiovascular disease[J]. J Clin Periodontol, 2012, 39(10):923-930.